Short Term - our price remains a function of the greed and fear...

Short Term - our price remains a function of the greed and fear of ASX participants.

Long term the price rely on participants who can weigh our:

Intangible Assets
- strategy
- execution of strategy
- strength of individual asset data points pre-clinical
- platform as an engine room of translating discoveries to the market

Tangible Assets
- VP-001 clinical data points - so far it’s safe and we should find out if it works as well as it did pre-clinical data pack suggest very soon
- PYC-001 preclinical data points - ‘gold standard’ linked Patient derived - NHP efficacy data screaming that it works very well as intended and it’s safe
- new CNS lead…

I have to learn to lean not on my own understanding but instead to trust in God that if PYC has found favor, a discerning and capable partner will step in to bridge for one/or more of our tangible assets a path to market - be it a combination of $ and expertise/infrastructure - something like this is out of our control except by the will of God a good path will form in time, if that be so then a CR will be needed despite the company’s best efforts to generate awareness/interest… when that time a valuation towards our intangible assets will materialize; again I don’t know how much this translates to - but one would think many multiples of the seeds we have sown (as Rohan says we are well below replacement value).